Articles tagged with: Sean R_ Hosein

U.S. simulation explores the intersection of PrEP and some sexually transmitted infections

published: October, 10, 2017 Written by // CATIE - HIV and Hep C Info Resource Categories // Social Media, As Prevention , Gay Men, CATIE, Treatment Guidelines -including when to start, General Health, Research, Sexual Health, Health, Treatment, Lifestyle, Media, CATIE - HIV and Hep C Info Resource

"The results of the researchers’ simulations show that PrEP should be considered as a package of interventions, of which STI screening and treatment are an important part. From Catie, Sean R. Hosein reports.

U.S. simulation explores the intersection of PrEP and some sexually transmitted infections

The use of medicines to prevent a person from becoming infected with HIV is called pre-exposure prophylaxis (PrEP). PrEP consists of two anti-HIV drugs—tenofovir DF and FTC—in one pill. In clinical trials with gay, bisexual and other men who have sex with men (MSM), PrEP has been highly effective in preventing the spread of HIV. According to a team of U.S. researchers who analysed data from several clinical trials, the consistent use of PrEP can reduce the risk of HIV infection “by more

Frailty, nerve injury and falls in middle-aged and older HIV-positive people

published: September, 15, 2017 Written by // CATIE - HIV and Hep C Info Resource Categories // Aging, Social Media, CATIE, General Health, Mental Health, Research, International , Living with HIV, Media, CATIE - HIV and Hep C Info Resource

From CATIE, Sean R. Hosein reports on a U.S. study that links such things as grip strength and gait speed with increased risk of falling.

Frailty, nerve injury and falls in middle-aged and older HIV-positive people

More HIV-positive people are living longer thanks to the use of potent combination anti-HIV therapy (ART). As HIV-positive people enter their middle age and senior years, they will have to grapple with one or more aging-related issues. One issue that can have a large impact on the health and quality of life of older people is falling. Older people who fall can injure themselves, and according to U.S. researchers, such injuries can make pre-existing problems, such as physical inactivity or weak

Ontario researchers find heart attacks occur earlier in people with HIV.

published: September, 12, 2017 Written by // CATIE - HIV and Hep C Info Resource Categories // Social Media, CATIE, Fitness and Exercise, Research, Health, Media

The researchers found that, on average, HIV-positive people tended to have a heart attack about 15 years before HIV-negative people. From CATIE, Sean R. Hosein reports on the CIHR HIV Trials Network Trial - Reprieve Study.

Ontario researchers find heart attacks occur earlier in people with HIV.

Studies have found that some HIV-positive people are at heightened risk for cardiovascular disease. The reasons for this are not clear but may be due to one or more of the following factors: smoking and/or other substance use elevated inflammation caused by HIV the presence of co-existing health conditions such as elevated blood pressure, type 2 diabetes, obesity exposure to older HIV medicines A number of studies from the U.S. have found that HIV-positive people who had a heart attac

Research finds that harm reduction and ART helped to reduce the spread of HIV in Vancouver

published: May, 02, 2017 Written by // CATIE - HIV and Hep C Info Resource Categories // Social Media, As Prevention , CATIE, Treatment Guidelines -including when to start, Research, Health, Treatment, CATIE - HIV and Hep C Info Resource

Sean R. Hosein of CATIE reports on research in Vancouver that attempted to study the relative impact that ART, harm reduction or both can have on the spread of HIV.

Research finds that harm reduction and ART helped to reduce the spread of HIV in Vancouver

In clinical trials, the early initiation of HIV treatment (ART) stabilizes the immune system and significantly reduces the risk of developing AIDS-related infections and cancers. This benefit of ART is so profound that researchers increasingly expect that many ART users will live into their senior years. Key to reaping the benefit of ART is achieving an undetectable level of HIV in the blood (viral load) and maintaining it through daily use of ART and regular checkups and laboratory monitori

The capsid inhibitor—a new class to enter clinical trials

published: April, 13, 2017 Written by // CATIE - HIV and Hep C Info Resource Categories // Social Media, As Prevention , African, Caribbean and Black, Gay Men, CATIE, Treatment Guidelines -including when to start, Youth, General Health, Women, Sexual Health, Health, International , Treatment, Media, CATIE - HIV and Hep C Info Resource

From CATIE: "This finding suggests that the capsid inhibitor has potential for intermittent dosing in people—perhaps every one or two months."

The capsid inhibitor—a new class to enter clinical trials

Most approved anti-HIV drugs work by interfering with an enzyme and/or protein that is needed by HIV-infected cells to make new viruses. A journey through the cell The capsid is the name given to the proteins that surround HIV’s genetic material. Upon HIV attaching itself to a target cell of the immune system, the virus sends its genetic material (RNA) into the cell. As the genetic material is surrounded by the capsid, it is protected from detection by the cell’s internal sensors. The ca

From the Conference on Retroviruses and Opportunistic Infections (CROI) 2017; new drugs, new hope and possible timelines

published: April, 07, 2017 Written by // CATIE - HIV and Hep C Info Resource Categories // Social Media, As Prevention , Gay Men, CATIE, Treatment Guidelines -including when to start, Research, Treatment, Media, CATIE - HIV and Hep C Info Resource

From CATIE, Sean R. Hosein reports on several new drugs that are in varying stages of development.

From the Conference on Retroviruses and Opportunistic Infections (CROI) 2017;  new drugs, new hope and possible timelines

Une version française est disponible ici. At the recent Conference on Retroviruses and Opportunistic Infections (CROI), which took place in Seattle from February 13 to 16, 2017, researchers presented data about new anti-HIV compounds in development, including the following: a new integrase inhibitor – bictegravir a new nuke (NRTI) – code-named GS-9131 a non-nuke (NNRTI) – doravirine a new protease inhibitor – code-named GS-PI1 a capsid inhibitor (a new cla

B.C. researchers explore life expectancy among HIV-positive people

published: March, 30, 2017 Written by // CATIE - HIV and Hep C Info Resource Categories // Aging, Social Media, Hep B and C, General Health, Mental Health, Health, Living with HIV, Media, CATIE - HIV and Hep C Info Resource

From CATIE, Sean R. Hosein reports on studies comparing the effect of comorbidities on life expectancy in people living with HIV and those who are HIV-negative.

B.C. researchers explore life expectancy among HIV-positive people

In the 20th century, life expectancy increased in Canada and other high-income countries thanks to improvements in medicine, better living conditions and so on. These changes have led some researchers to focus on something called health-adjusted life expectancy: exploring the number of years a person can expect to live in good and bad health and taking into account age-related illness, death and disability. Among many HIV-positive people in Canada and other high-income countries there has be

Toronto-led team explores different PrEP deployment scenarios

published: October, 05, 2016 Written by // CATIE - HIV and Hep C Info Resource Categories // Social Media, As Prevention , CATIE, Treatment Guidelines -including when to start, Research, Health, Treatment, CATIE - HIV and Hep C Info Resource

Fascinating projections from St Michael's Hospital on the impact on HIV diagnoses in Toronto when employing different PrEP scenarios. From the CATIE blog, Sean R. Hosein reports.

Toronto-led team explores different PrEP deployment scenarios

Une version francaise est disponible ici. Truvada is a pill containing the following two anti-HIV drugs: tenofovir DF – 300 mg FTC (emtricitabine) – 200 mg Health Canada has approved the daily use of Truvada to reduce the risk of sexual transmission of HIV as part of a series of prevention measures that includes the following: testing for HIV prior to initiation of Truvada screening for and, when necessary, treatment of sexually transmitted infections regular and frequent tes